The FDA approved Ycanth (cantharidin) for the topical (used on the skin) treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. Ycanth is the first FDA-approved treatment for molluscum. Ycanth is administered to patients only by health care providers. Providers apply a single application of Ycanth on the areas of patients’ skin with molluscum bumps every 3 weeks as needed.
Molluscum contagiosum is a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated. These bumps can happen alone or in groups almost anywhere on the skin, including the face, neck, arms, legs, stomach, and genital area. Molluscum is transmitted by skin-to-skin contact and can affect anyone at any age, though it’s most common among children under 10.
The most common adverse reactions to Ycanth occurred at the application site, and included blistering, pain, itching, scabbing, reddening, discoloration, dryness, edema (swelling), and erosion of the skin. Life threatening or fatal toxicities can occur if administered orally. Contact with the treatment area should be avoided, including oral contact, after treatment. Ycanth is flammable, even after drying. Patients should avoid fire, flame, or smoking near lesion(s) during treatment and after application until removed.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!